Literature DB >> 7825569

Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia.

A M Engbersen1, D G Franken, G H Boers, E M Stevens, F J Trijbels, H J Blom.   

Abstract

Thermolability of 5,10-methylenetetrahydrofolate reductase (MTHFR) was examined as a possible cause of mild hyperhomocysteinemia in patients with premature vascular disease. Control subjects and vascular patients with mild hyperhomocysteinemia and with normohomocysteinemia were studied. The mean (+/- SD) specific MTHFR activity in lymphocytes of 22 control subjects was 15.6 (+/- 4.7) nmol CH2O/mg protein/h (range: 9.1-26.6), and the residual activity (+/- SD) after heat inactivation for 5 min at 46 degrees C was 55.3 (+/- 12.0)% (range: 35.9-78.3). By measurement of MTHFR activity, two distinct subgroups of hyperhomocysteinemic patients became evident. One group (n = 11) had thermolabile MTHFR with a mean (+/- SD) specific activity of 8.7 (+/- 2.1) nmol CH2O/mg protein/h (range: 5.5-12.7) and a residual activity, after heat inactivation, ranging from 0% to 33%. The other group (n = 28) had normal specific activity (+/- SD) of 21.5 (+/- 7.2) nmol CH2O/mg protein/h (range: 10.0-39.0) and a normal residual activity (+/- SD) of 53.8 (+/- 9.2)% (range: 33.1-71.5) after heat inactivation. The mean (+/- SD) specific activity of 29 normohomocysteinemic patients was 20.7 (+/- 6.5) nmol CH2O/mg protein/h (range: 9.4-33.8), and the mean (+/- SD) residual activity after heat inactivation was 58.2 (+/- 10.2)% (range: 43.0-82.0). Thus, in 28% of the hyperhomocysteinemic patients with premature vascular disease, abnormal homocysteine metabolism could be attributed to thermolabile MTHFR.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7825569      PMCID: PMC1801334     

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  24 in total

1.  Methylenetetrahydrofolate reductase in cultured human cells. II. Genetic and biochemical studies of methylenetetrahydrofolate reductase deficiency.

Authors:  D S Rosenblatt; R W Erbe
Journal:  Pediatr Res       Date:  1977-11       Impact factor: 3.756

2.  Prenatal diagnosis for methylenetetrahydrofolate reductase deficiency.

Authors:  U Wendel; U Claussen; E Diekmann
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

3.  Betaine in the treatment of homocystinuria.

Authors:  N J Benevenga
Journal:  N Engl J Med       Date:  1984-01-26       Impact factor: 91.245

4.  Release of formaldehyde from denture base polymers.

Authors:  I E Ruyter
Journal:  Acta Odontol Scand       Date:  1980       Impact factor: 2.331

5.  Infantile type of homocystinuria with 5,10-methylenetetrahydrofolate reductase deficiency.

Authors:  Y Wada; K Narisawa; T Arakawa
Journal:  Monogr Hum Genet       Date:  1978

6.  Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase.

Authors:  S S Kang; J Zhou; P W Wong; J Kowalisyn; G Strokosch
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

7.  Treatment of mild hyperhomocysteinemia in vascular disease patients.

Authors:  D G Franken; G H Boers; H J Blom; F J Trijbels; P W Kloppenborg
Journal:  Arterioscler Thromb       Date:  1994-03

8.  A study of cardiovascular risk in heterozygotes for homocystinuria.

Authors:  S H Mudd; R Havlik; H L Levy; V A McKusick; M Feinleib
Journal:  Am J Hum Genet       Date:  1981-11       Impact factor: 11.025

9.  Thermolabile methylenetetrahydrofolate reductase in patients with coronary artery disease.

Authors:  S S Kang; P W Wong; J M Zhou; J Sora; M Lessick; N Ruggie; G Grcevich
Journal:  Metabolism       Date:  1988-07       Impact factor: 8.694

10.  Intermediate hyperhomocysteinemia resulting from compound heterozygosity of methylenetetrahydrofolate reductase mutations.

Authors:  S S Kang; P W Wong; H G Bock; A Horwitz; A Grix
Journal:  Am J Hum Genet       Date:  1991-03       Impact factor: 11.025

View more
  52 in total

1.  Rapid diagnosis and methionine administration: basis for a favourable outcome in a patient with methylene tetrahydrofolate reductase deficiency.

Authors:  N G Abeling; A H van Gennip; H Blom; R A Wevers; P Vreken; H L van Tinteren; H D Bakker
Journal:  J Inherit Metab Dis       Date:  1999-05       Impact factor: 4.982

Review 2.  Hyperhomocysteinaemia and associated disease.

Authors:  R C Bakker; D P Brandjes
Journal:  Pharm World Sci       Date:  1997-06

3.  Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study.

Authors:  A B Guttormsen; P M Ueland; I Nesthus; O Nygård; J Schneede; S E Vollset; H Refsum
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

4.  Identification and functional analysis of cystathionine beta-synthase gene mutations in patients with homocystinuria.

Authors:  Sook-Jin Lee; Dong Hwan Lee; Han-Wook Yoo; Soo Kyung Koo; Eun-Sook Park; Joo-Won Park; Hun Gil Lim; Sung-Chul Jung
Journal:  J Hum Genet       Date:  2005-10-05       Impact factor: 3.172

5.  Elevated total plasma homocysteine and 677C-->T mutation of the 5,10-methylenetetrahydrofolate reductase gene in thrombotic vascular disease.

Authors:  R de Franchis; F P Mancini; A D'Angelo; G Sebastio; I Fermo; V de Stefano; M Margaglione; G Mazzola; G di Minno; G Andria
Journal:  Am J Hum Genet       Date:  1996-07       Impact factor: 11.025

6.  The frequency of the methylenetetrahydrofolate reductase-gene mutation varies with age in the normal population.

Authors:  S Matsushita; T Muramatsu; H Arai; T Matsui; S Higuchi
Journal:  Am J Hum Genet       Date:  1997-12       Impact factor: 11.025

Review 7.  Molecular genetics of methylenetetrahydrofolate reductase deficiency.

Authors:  R Rozen
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

8.  Polymorphisms of the methylenetetrahydrofolate reductase, vascular endothelial growth factor, endothelial nitric oxide synthase, monocyte chemoattractant protein-1 and apolipoprotein E genes are not associated with carotid intima-media thickness.

Authors:  Emin Alioglu; Ugur Turk; Sirri Cam; Abbasali Abbasaliyev; Istemihan Tengiz; Ertugrul Ercan
Journal:  Can J Cardiol       Date:  2009-01       Impact factor: 5.223

Review 9.  Insights into metabolic mechanisms underlying folate-responsive neural tube defects: a minireview.

Authors:  Anna E Beaudin; Patrick J Stover
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-04

10.  Hyperhomocysteinemia and low plasma folate as risk factors for central retinal vein occlusion: a case-control study in a Chinese population.

Authors:  Wei Gao; Yu-Sheng Wang; Peng Zhang; Hai-Yan Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-15       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.